Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis-Reference-Cited by-同舟云学术

Impact of Driver Mutations on Metastasis-Free Survival in Uveal Melanoma: A Meta-Analysis

Published:2024-07-10 Issue:14 Volume:16 Page:2510
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Lamas-Francis David¹^ORCID,Rodríguez-Fernández Carmen Antía²³^ORCID,de Esteban-Maciñeira Elia¹^ORCID,Silva-Rodríguez Paula⁴⁵,Pardo María⁶^ORCID,Bande-Rodríguez Manuel¹,Blanco-Teijeiro María José¹

Affiliation:

1. Department of Ophthalmology, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain

2. Department of Ophthalmology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain

3. FarmaChusLab Group, Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain

4. Fundación Pública Galega de Medicina Xenómica, 15706 Santiago de Compostela, Spain

5. Translational Ophthalmology Group, Health Research of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain

6. Obesidomics Group, Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain

Abstract

The prognosis of uveal melanoma is significantly influenced by the risk of metastasis, which varies according to clinical and genetic features. Driver mutations can predict the likelihood of disease progression and survival, although the data in the literature are inconsistent. This meta-analysis aimed to evaluate the prognostic significance of driver mutations, including GNAQ, GNA11, BAP1, and SF3B1, in the advancement of uveal melanoma. A comprehensive search of databases yielded relevant studies, and data from 13 studies (848 eyes) were synthesized to assess the impact of these mutations on metastasis-free survival. The BAP1 mutation and negative immunohistochemistry were associated with a higher risk of metastasis (logHR = 1.44, 95% CI 1.05–1.83). GNAQ, GNA11, and SF3B1 mutations did not show a significant increase in risk. In summary, BAP1 has proven to reliably predict the likelihood of disease progression in uveal melanoma, while further studies are needed to establish the significance of other driver mutations.

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/14/2510/pdf

Reference44 articles.

1. Uveal Melanoma;Jager;Nat. Rev. Dis. Primers,2020

2. Pavlick, A.C., and Finger, P.T. (2018). Systemic Evaluation and Management of Patients with Metastatic Uveal Melanoma. Ryan’s Retina, Elsevier. [6th ed.].

3. Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma;Kujala;Investig. Ophthalmol. Vis. Sci.,2003

4. International Validation of the American Joint Committee on Cancer’s 7th Edition Classification of Uveal Melanoma;Simpson;JAMA Ophthalmol.,2015

5. Microcirculation and Tumor-Infiltrating Macrophages in Choroidal and Ciliary Body Melanoma and Corresponding Metastases;Toivonen;Investig. Ophthalmol. Vis. Sci.,2004